arrow_back Back to Series
Conversations in Healthcare

Drugs to Watch: What are the drivers and barriers for future blockbusters?

Read the transcript of the episode

About episode

Clarivate pharma market experts break down the opportunities and potential threats for 2021’s Drugs to Watch™ – four drugs expected to be blockbusters by 2025.

Featuring

Joan Tur
Principal Content Specialist, Competitive Intelligence
Clarivate
Carolina do Pazo, M.Sc.
Senior Business Insights Analyst
Clarivate
Raina Priyadarshini
Principal Analyst
Clarivate
Mohit Nasa (B.Pharm, M.B.A.)
Manager, BioPharma Insights
Clarivate
Dominika Rudnicka-Noulin, Ph.D., M.Sc.
Senior Business Insights Analyst, Cardiovascular, Metabolic, Renal, and Hematologic (CMRH) Disorders
Clarivate
​​Jonathan Searles
Senior Director of CNS/Ophthalmology Therapy
Clarivate

About Conversations in Healthcare

Clarivate Conversations in Healthcare is a series of candid interviews with industry leaders and experts on the key trends and challenges that are shaping the future of the healthcare industry. Topics include from clinical innovation, deal-making, market access and regulatory dynamics, data and technology, new engagement models, patient centricity, diversity, COVID-19 and much more. Subscribe for episodes here.

Episodes